BridgeMD
Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases
EU CTIS ID: 2024-517149-15-00
What this study is testing
Applying a systemic control with precision approach over the course of the rectal cancer therapy is logistically feasible Applying a systemic control and precision approach as a treatment strategy, recurrence-free survival of rectal cancer patients is improved
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1) rectal adenocarcinoma, 2) WHO performance status 0-1, assessed by the MDT to be able to undergo CAPOX (capecitabine and oxaliplatin) treatment, 3) mrEMVI+ and 4) assessed by the MDT to require either RT or CRT by the current standards. In general, indications for clinical rectal carcinoma MDT to recommend RT or CRT are: T3-4 tumor at mid- or low rectum location, involvement of lymph nodes, threatened operative margin or mrEMVI
You likely can't join if
- 1.) deficient MMR status, non-DPYD genotype 2) a contraindication to capecitabine, oxaliplatin or RT, 3) failing in blood tests that describe the adequate circulatory 4) liver and kidney function for chemotherapy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.